Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylpiperazine SCHEMBL28185035 | 0.94 | ALDH1A1 (0.41) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| SCHEMBL6632282 | 0.92 | — | — | |
| Methylpiperazine SCHEMBL28185042 | 0.91 | CXCR4 (0.41) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| N-Methylpiperidine SCHEMBL27667330 | 0.88 | CA2 (0.42) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| N-Methylpiperidine SCHEMBL1038414 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| SCHEMBL14299960 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| SCHEMBL14299867 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| N-Methylpiperidine SCHEMBL9009614 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| SCHEMBL16790161 | 0.88 | ALDH1A1 (0.53) | ALDH1A1CXCR4CA2CHKAKDM4E | |
| SCHEMBL272114 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040994-B2 | Cobalt complexes, process for preparation and use thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2021-06-22 | — | — | US | claimed |
| WO-2002079753-A2 | 2-AMINOBENZOXAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040994-B2 | Cobalt complexes, process for preparation and use thereof | MAPT, PSEN1, PSEN2 | ALDH1A1 3029/4885CXCR4 2928/4885CA2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.